Percutaneous Coronary Intervention Guidelines Microchapters |
PCI Approaches: |
---|
CAD Revascularization: |
Pre-procedural Considerations: |
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
Quality and Performance Considerations: |
Percutaneous coronary intervention revascularization before non-cardiac surgery On the Web |
American Roentgen Ray Society Images of Percutaneous coronary intervention revascularization before non-cardiac surgery |
FDA on Percutaneous coronary intervention revascularization before non-cardiac surgery |
CDC on Percutaneous coronary intervention revascularization before non-cardiac surgery |
Percutaneous coronary intervention revascularization before non-cardiac surgery in the news |
Blogs on Percutaneous coronary intervention revascularization before non-cardiac surgery |
Directions to Hospitals Treating Percutaneous Coronary Intervention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Class I |
" 1. Coronary revascularization before noncardiac surgery is useful in patients with stable angina who have significant left main coronary artery stenosis (Level of Evidence: A) " |
" 2. Coronary revascularization before noncardiac surgery is useful in patients with stable angina who have 3-vessel disease (Survival benefit is greater when left ventricular ejection fraction is less than 0.50). (Level of Evidence: A) " |
" 3. Coronary revascularization before noncardiac surgery is useful in patients with stable angina who have 2-vessel disease with significant proximal left anterior descending stenosis and either ejection fraction less than 0.50 or demonstrable ischemia on noninvasive testing (Level of Evidence: A)" |
" 4. Coronary revascularization before noncardiac surgery is recommended for patients with high-risk unstable angina or non ST-segment elevation myocardial infarction (MI) (Level of Evidence: A) " |
" 5. Coronary revascularization before noncardiac surgery is recommended in patients with acuteST elevation MI.(Level of Evidence: A) " |
Class III (No Benefit) |
" 1. Routine prophylactic coronary revascularizationshould not be performed in patients with stable CAD before noncardiac surgery.[3][4](Level of Evidence: B)" |
" 2. Elective non-cardiac surgery should not be performed in the 4 to 6 weeks after balloon angioplasty or BMS implantation or the 12 months after DES implantation in patients in whom theP2Y12 inhibitor will need to be discontinued peri-operatively.[5][6][7][8](Level of Evidence: B)" |
Class IIa |
" 1. For patients who require PCI and are scheduled for elective non-cardiac surgery in the subsequent 12 months, a strategy of balloon angioplasty, or BMS implantation followed by 4 to 6 weeks of dual antiplatelet therapy (DAPT), is reasonable.[9][10][11][7][12][6][13] (Level of Evidence: B)" |
" 2. For patients with drug eluting stent (DES) who must undergo urgent surgical procedures that mandate the discontinuation of dual antiplatelet therapy (DAPT), it is reasonable to continue aspirin if possible and restart the P2Y12 inhibitor as soon as possible in the immediate postoperative period.[11][1](Level of Evidence: C)" |
Class IIb |
" 1. The usefulness of preoperative coronary revascularization is not well established in high-risk ischemic patients (eg, abnormal dobutamine stress echocardiography with at least 5 segments of wall-motion abnormalities)(Level of Evidence: C) " |
" 2. The usefulness of preoperative coronary revascularization is not well established for low-risk ischemic patients with an abnormal dobutamine stress echocardiography (segments 1 to 4). (Level of Evidence: B) " |
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)
|month=
ignored (help)